ArriVent BioPharma (AVBP) vs Geron (GERN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Geron (GERN) has outperformed ArriVent BioPharma (AVBP) over the past year, losing 11.6% versus a loss of 19.7%. ArriVent BioPharma is the larger company by market cap ($823.9 million vs $783.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | GERN |
|---|---|---|
| Share price | $16.71 | $1.22 |
| Market cap | $823.93M | $783.82M |
| 1-day change | -1.07% | +1.67% |
| YTD return | -16.95% | -7.58% |
| 1-year return | -19.74% | -11.59% |
| 5-year return | — | -13.48% |
| Forward P/E | — | 30.50 |
| EPS (TTM) | $-3.62 | $-0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.83 | $2.01 |
| 52-week low | $11.36 | $1.04 |
| Distance from 52-week high | -53.36% | -39.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +82.53% | +248.36% |
| Average volume | 908.55K | 10.07M |
| Shares outstanding | 49.31M | 642.47M |
| Employees | 77 | 258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
AVBP vs GERN FAQ
Which is bigger, ArriVent BioPharma or Geron?
ArriVent BioPharma (AVBP) is larger, with a market capitalization of $823.93M compared with $783.82M for Geron (GERN).
Which stock has performed better over the past year, AVBP or GERN?
GERN returned -11.59% over the past 12 months, compared with -19.74% for AVBP (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and Geron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.